Immunogenicity analyses

The immunogenicity of a therapeutic compound is an essential characteristic of a therapeutic product. Immuno-activating therapies (e.g. vaccination or anti-tumor therapy) depend on a certain amount of immunogenicity to activate the immune system and direct the type of immune response induced. Especially in the case of protein drugs (biologicals such as antibodies and therapeutic proteins) immunogenicity against the drug may lead to formation of inhibitory anti-drug antibodies which is detrimental for therapy efficacy and specifically a risk for a therapeutic compound that will be used for prolonged treatment. Although immunogenicity is routinely predicted upon drug development and tested in animal studies, to date monitoring of the true immunogenicity of the drug in samples of volunteers or patients treated with the compound is becoming increasingly recognized to be important and required by regulatory agencies.

Sanquin offers a selection of assays to determine the immunogenicity of a compound. We are specialized in measuring anti-biologicals antibodies against a range of existing biologicals (both antibody and non-antibody), and also offer development of assays to determine anti-drug antibodies against novel therapeutic compounds.

In addition, Sanquin offers assays to analyze and characterize antigen-specific CD8 T cell responses using HLA class I tetramer staining (CD8: MHC multimer analyses), antigen-specific CD4 T cells by use of CD40L assay and antigen-specific B cells.

Sanquin offers a fast, reliable method to find immunogenic peptides binding to HLA class I molecules, hereby identifying new CD8 T cell epitopes (HLA class I (UV-induced peptide exchange technology). With UV-induced peptide exchange you can screen for binders in a high-throughput fashion. This method speeds up the discovery of peptides of interest that bind to HLA class I and are potentially immunogenic.

Contact us for more information or browse through our assays.

Also see:

 

Last edited on: 4 November 2015